Morgan Stanley Starts Bicara Therapeutics Inc (BCAX) at Overweight

Morgan Stanley analyst Judah Frommer initiates coverage on Bicara Therapeutics Inc (NASDAQ: BCAX) with a Overweight rating and a price target of $35.00.

The analyst comments: "We initiate coverage of BCAX with an OW rating and $35 price target. Bicara Therapeutics is a mid-clinical stage (soon to be late-stage) biotech with a validated bifunctional antibody (i.e., binds 2 antigens) approach to treating EGFR-expressing tumors. Its lead candidate, ficerafusp alfa (fifa), inhibits 2 clinically validated biological targets in cancer drug development, EGFR and TGF-ß. Fifa's dual-targeting mechanism may drive superior efficacy versus standard of care while addressing safety limitations of prior approaches. Fifa is being developed as a first-line treatment for recurrent/metastatic head & neck squamous cell carcinoma, a disease with poor prognosis and where anti-EGFR therapy is already approved."

For an analyst ratings summary and ratings history on Bicara Therapeutics Inc click here. For more ratings news on Bicara Therapeutics Inc click here.

Shares of Bicara Therapeutics Inc closed at $24.45 yesterday.

You May Also Be Interested In

• Bicara Therapeutics Inc (BCAX) PT Raised to $20 at Mizuho
• Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
• Freedom Broker Double Downgrades Mosaic (MOS) to Sell